Diabetes & metabolism最新文献

英文中文

Type 2 diabetes and cardiorenal syndromes. A nationwide French hospital cohort study 2型糖尿病和心肾综合征。一项法国全国医院队列研究

IF 7.2 2区医学 Q1 Biochemistry, Genetics and Molecular Biology

Diabetes & metabolism

Pub Date : 2023-05-01 DOI: 10.1016/j.diabet.2023.101441

Valentin Maisons , Jean-Michel Halimi , Grégoire Fauchier , Jean-Baptiste de Fréminville , Nicolas Goin , Juliette Gueguen , Philippe Gatault , Bénédicte Sautenet , Denis Angoulvant , Julien Herbert , Arnaud Bisson , Pierre-Henri Ducluzeau , Laurent Fauchier

Aim

Type 2 diabetes mellitus (T2DM) is a risk factor for cardiac and renal complications; its effect on cardiorenal syndromes is unknown.

Methods

In a French nationwide cohort of 5,123,193 patients hospitalized in 2012 with ≥5 years of follow-up, we assessed the effect of T2DM on cardiorenal syndrome (CRS) (using cardiorenal, renocardiac, and simultaneous subtypes) incidence and outcomes using 1:1 propensity matching.

Results

Among 4,605,236 adults without cardiorenal syndrome, 380,581 (8.5%) with T2DM were matched to 380,581 adults without T2DM. During follow-up, CRS occurred in 104,788 patients: simultaneous n = 25,225 (24.0%); cardiorenal n = 51,745 (49.4%); renocardiac n = 27,818 (26.5%). T2DM doubled the risk of incident CRS (1.30% versus 0.65%/year; adjusted hazard ratio (HR) for any cardiorenal syndrome: 2.14 [95% confidence interval 2.10;2.19]; renocardiac: 2.43 [2.34;2.53]; cardiorenal: 2.09 [2.03;2.15]; simultaneous: 1.94 [1.86;2.03]. Among the 26,396 adults with CRS in 2012, 11,355 (43.0%) had T2DM and were younger than non-diabetic adults (77.4 ± 9.5 versus 82.3 ± 10.0); 8,314 patients with T2DM were matched to 8,314 patients without. T2DM increased risk of: end-stage kidney disease, adjusted HR 1.50 [1.39;1.62]; myocardial infarction 1.35 [1.19;1.53]; cardiovascular death 1.20 [1.13;1.27]; heart failure 1.17 [1.12;1.21]; and all-cause death 1.09 [1.06;1.13], but not ischemic stroke.

Conclusion

Patients with T2DM represent almost half of patients with CRS and are younger than their non-diabetic counterparts. T2DM doubles the risk of CRS and increases the risk of death, cardiovascular outcome, and end-stage kidney disease but not ischemic stroke after CRS.

2型糖尿病（T2DM）是心脏和肾脏并发症的危险因素；其对心肾综合征的影响尚不清楚。方法在法国全国范围内2012年住院且随访时间≥5年的5123193名患者队列中，我们使用1:1倾向匹配评估了T2DM对心肾综合征（CRS）（使用心肾、肾心和同时亚型）发病率和结果的影响。结果在4605236例无心肾综合征的成人中，380581例（8.5%）T2DM患者与380581名无T2DM患者相匹配。在随访期间，104788名患者发生CRS：同时发生的n=25225（24.0%）；心肾n=51745（49.4%）；肾心综合征n=27818（26.5%）。T2DM使CRS事件的风险增加了一倍（1.30%对0.65%/年；任何心肾综合征的调整后危险比（HR）：2.14[95%置信区间2.10；2.19]；肾心功能：2.43[2.34；2.53]；心肾：2.09[2.03；2.15]；同时：1.94[1.86；2.03]。在2012年的26396名CRS成年人中，11355人（43.0%）患有T2DM，并且比非糖尿病成年人年轻（77.4±9.5对82.3±10.0）；8314例T2DM患者与8314例非T2DM患者相匹配。T2DM增加了患终末期肾病的风险，调整后的HR为1.50[1.39；1.62]；心肌梗死1.35[1.19；1.53]；心血管死亡1.20[1.13；1.27]；心力衰竭1.17[1.12；1.21]；全因死亡1.09[1.06；1.13]，但不包括缺血性中风。结论T2DM患者几乎占CRS患者的一半，并且比非糖尿病患者年轻。T2DM使CRS的风险增加一倍，并增加CRS后死亡、心血管结局和终末期肾病的风险，但不增加缺血性中风的风险。

{"title":"Type 2 diabetes and cardiorenal syndromes. A nationwide French hospital cohort study","authors":"Valentin Maisons , Jean-Michel Halimi , Grégoire Fauchier , Jean-Baptiste de Fréminville , Nicolas Goin , Juliette Gueguen , Philippe Gatault , Bénédicte Sautenet , Denis Angoulvant , Julien Herbert , Arnaud Bisson , Pierre-Henri Ducluzeau , Laurent Fauchier","doi":"10.1016/j.diabet.2023.101441","DOIUrl":"10.1016/j.diabet.2023.101441","url":null,"abstract":"<div><h3>Aim</h3><p>Type 2 diabetes mellitus (T2DM) is a risk factor for cardiac and renal complications; its effect on cardiorenal syndromes is unknown.</p></div><div><h3>Methods</h3><p>In a French nationwide cohort of 5,123,193 patients hospitalized in 2012 with ≥5 years of follow-up, we assessed the effect of T2DM on cardiorenal syndrome (CRS) (using cardiorenal, renocardiac, and simultaneous subtypes) incidence and outcomes using 1:1 propensity matching.</p></div><div><h3>Results</h3><p>Among 4,605,236 adults without cardiorenal syndrome, 380,581 (8.5%) with T2DM were matched to 380,581 adults without T2DM. During follow-up, CRS occurred in 104,788 patients: simultaneous <em>n</em> = 25,225 (24.0%); cardiorenal <em>n</em> = 51,745 (49.4%); renocardiac <em>n</em> = 27,818 (26.5%). T2DM doubled the risk of incident CRS (1.30% versus 0.65%/year; adjusted hazard ratio (HR) for any cardiorenal syndrome: 2.14 [95% confidence interval 2.10;2.19]; renocardiac: 2.43 [2.34;2.53]; cardiorenal: 2.09 [2.03;2.15]; simultaneous: 1.94 [1.86;2.03]. Among the 26,396 adults with CRS in 2012, 11,355 (43.0%) had T2DM and were younger than non-diabetic adults (77.4 ± 9.5 versus 82.3 ± 10.0); 8,314 patients with T2DM were matched to 8,314 patients without. T2DM increased risk of: end-stage kidney disease, adjusted HR 1.50 [1.39;1.62]; myocardial infarction 1.35 [1.19;1.53]; cardiovascular death 1.20 [1.13;1.27]; heart failure 1.17 [1.12;1.21]; and all-cause death 1.09 [1.06;1.13], but not ischemic stroke.</p></div><div><h3>Conclusion</h3><p>Patients with T2DM represent almost half of patients with CRS and are younger than their non-diabetic counterparts. T2DM doubles the risk of CRS and increases the risk of death, cardiovascular outcome, and end-stage kidney disease but not ischemic stroke after CRS.</p></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":null,"pages":null},"PeriodicalIF":7.2,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9831525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Contents - Page 1 目录-第一页

IF 7.2 2区医学 Q1 Biochemistry, Genetics and Molecular Biology

Diabetes & metabolism

Pub Date : 2023-05-01 DOI: 10.1016/S1262-3636(23)00033-2

引用次数: 0

Modification of the all-cause and cardiovascular disease related mortality risk with changes in the metabolic syndrome status: a population-based prospective cohort study in Taiwan 代谢综合征状态改变对全因及心血管疾病相关死亡风险的影响:台湾一项基于人群的前瞻性队列研究

IF 7.2 2区医学 Q1 Biochemistry, Genetics and Molecular Biology

Diabetes & metabolism

Pub Date : 2023-05-01 DOI: 10.1016/j.diabet.2022.101415

Yun-Ju Lai , Yung-Feng Yen , Li-Jung Chen , Li-Fei Hsu , Matthew N. Ahmadi , Elif Inan-Eroglu , Po-Wen Ku , Emmanuel Stamatakis

Aim

To examine whether changes in metabolic syndrome (MetS) status over time are associated with risk of all-cause and cardiovascular disease related (CVD) mortality.

Methods

This prospective cohort study consisted of 544,749 individuals who participated in a self-funded comprehensive health surveillance program offered by Taiwan MJ Health Management Institution between 1998 and 2016. We included 236,216 adults who had at least two repeated MetS measures 5.9 (4.6) years apart and were followed up for mortality over 18.8 (5.2) years. Participants were classified according to the change in their MetS status as follows: MetS-free at both time points (n = 173,116), MetS-developed (n = 22,607), MetS-recovered (n = 13,616), and MetS-persistent (n = 26,877). Multivariable Cox proportional hazards model was used to determine the association between change in MetS status and risk of all-cause and CVD mortality.

Results

Over the 4,436,842 person-years follow-up period, 14,226 participants died, including 2671 (19%) of CVD-related causes. The crude CVD mortality rate per 1000 person-years in the study groups were MetS-free, 0.32; MetS-developed, 0.75; MetS-recovered, 1.22; and MetS-persistent, 2.00 (P < 0.001). Compared to the persistent MetS group, participants in the MetS-recovered group had a lower risk of all-cause (adjusted hazard ratio [aHR], 0.87; 95%CI, 0.82–0.92) and CVD mortality (aHR, 0.81; 95% confidence interval [CI], 0.71–0.93). Development of MetS increased the risk for all-cause (aHR, 1.11; 95%CI, 1.05–1.17) and CVD mortality (aHR, 1.22; 95%CI, 1.07–1.39), compared to the MetS-free group.

Conclusion

Recovery from MetS was significantly associated with a lower risk of all-cause and CVD mortality, whereas development of MetS was associated with increased risk.

目的研究代谢综合征（MetS）状态随时间的变化是否与全因和心血管疾病相关（CVD）死亡率的风险相关。方法这项前瞻性队列研究包括544749人，他们参加了台湾MJ健康管理机构在1998年至2016年期间提供的自费综合健康监测项目。我们纳入了236216名成年人，他们至少有两次重复的MetS测量，间隔5.9（4.6）年，并对18.8（5.2）年的死亡率进行了随访。根据MetS状态的变化，参与者被分类如下：两个时间点的MetS无症状（n=173116）、MetS发展（n=22607）、MetS恢复（n=13616）和MetS持续（n=26877）。使用多变量Cox比例危险模型来确定MetS状态的变化与全因和CVD死亡率风险之间的关系。结果在4436842人年的随访期内，14226名参与者死亡，其中2671人（19%）死于心血管疾病相关原因。研究组中每1000人-年的粗CVD死亡率为0.32；MetS发展，0.75；MetS恢复，1.22；MetS持续2.00（P＜0.001）。与持续MetS组相比，MetS康复组的参与者全因风险（调整后的危险比[aHR]，0.87；95%CI，0.82–0.92）和心血管疾病死亡率（aHR，0.81；95%置信区间[CI]，0.71–0.93）较低。与无MetS组相比，MetS的发展增加了全因风险，aHR，1.11；95%可信区间，1.05–1.17）和心血管病死亡率（aHR1.22；95%CI，1.07–1.39）。结论MetS的康复与全因和CVD死亡率的降低显著相关，而MetS的发展与风险的增加相关。

{"title":"Modification of the all-cause and cardiovascular disease related mortality risk with changes in the metabolic syndrome status: a population-based prospective cohort study in Taiwan","authors":"Yun-Ju Lai , Yung-Feng Yen , Li-Jung Chen , Li-Fei Hsu , Matthew N. Ahmadi , Elif Inan-Eroglu , Po-Wen Ku , Emmanuel Stamatakis","doi":"10.1016/j.diabet.2022.101415","DOIUrl":"10.1016/j.diabet.2022.101415","url":null,"abstract":"<div><h3>Aim</h3><p>To examine whether changes in metabolic syndrome (MetS) status over time are associated with risk of all-cause and cardiovascular disease related (CVD) mortality.</p></div><div><h3>Methods</h3><p>This prospective cohort study consisted of 544,749 individuals who participated in a self-funded comprehensive health surveillance program offered by Taiwan MJ Health Management Institution between 1998 and 2016. We included 236,216 adults who had at least two repeated MetS measures 5.9 (4.6) years apart and were followed up for mortality over 18.8 (5.2) years. Participants were classified according to the change in their MetS status as follows: MetS-free at both time points (<em>n</em> = 173,116), MetS-developed (<em>n</em> = 22,607), MetS-recovered (<em>n</em> = 13,616), and MetS-persistent (<em>n</em> = 26,877). Multivariable Cox proportional hazards model was used to determine the association between change in MetS status and risk of all-cause and CVD mortality.</p></div><div><h3>Results</h3><p>Over the 4,436,842 person-years follow-up period, 14,226 participants died, including 2671 (19%) of CVD-related causes. The crude CVD mortality rate per 1000 person-years in the study groups were MetS-free, 0.32; MetS-developed, 0.75; MetS-recovered, 1.22; and MetS-persistent, 2.00 (<em>P</em> < 0.001). Compared to the persistent MetS group, participants in the MetS-recovered group had a lower risk of all-cause (adjusted hazard ratio [aHR], 0.87; 95%CI, 0.82–0.92) and CVD mortality (aHR, 0.81; 95% confidence interval [CI], 0.71–0.93). Development of MetS increased the risk for all-cause (aHR, 1.11; 95%CI, 1.05–1.17) and CVD mortality (aHR, 1.22; 95%CI, 1.07–1.39), compared to the MetS-free group.</p></div><div><h3>Conclusion</h3><p>Recovery from MetS was significantly associated with a lower risk of all-cause and CVD mortality, whereas development of MetS was associated with increased risk.</p></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":null,"pages":null},"PeriodicalIF":7.2,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10217380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Reply to Dr. Chiang's comments 对蒋意见的答复

IF 7.2 2区医学 Q1 Biochemistry, Genetics and Molecular Biology

Diabetes & metabolism

Pub Date : 2023-05-01 DOI: 10.1016/j.diabet.2023.101445

Giovanni Targher , Alessandro Mantovani , Christopher D. Byrne

引用次数: 0

Incidence of new-onset type 1 diabetes during Covid-19 pandemic: A French nationwide population-based study Covid-19大流行期间新发1型糖尿病的发病率:一项基于法国全国人群的研究

IF 7.2 2区医学 Q1 Biochemistry, Genetics and Molecular Biology

Diabetes & metabolism

Pub Date : 2023-05-01 DOI: 10.1016/j.diabet.2023.101425

Anne-Sophie Mariet , Jean-Michel Petit , Eric Benzenine , Catherine Quantin , Benjamin Bouillet

Aim

The association between infection with SARS-CoV-2 and the development of new-onset type 1 diabetes mellitus (T1DM) is unclear. The aim of this study was to examine the impact of the Covid-19 pandemic on the hospitalization rates for new-onset T1DM and diabetic ketoacidosis at diagnosis, in metropolitan France.

Methods

This nationwide retrospective cohort study included hospital data on all patients aged 1 to 35 years old, hospitalized in France due to onset of T1DM, in 2020 and 2021 compared to 2019.

Results

Apart from a decrease during the lockdown in 2020, the number of hospitalizations due to new-onset T1DM was not significantly different in 2020 and 2021 than it was in 2019. In the regions most affected by Covid-19 and covering 7,995,449 inhabitants aged from 1 to 35 years old, standardized hospitalization rates were not significantly different in 2020 and in 2021 compared with 2019. The number of hospitalizations for diabetic ketoacidosis at diagnosis was not significantly different after week 14 in 2020 and in 2021 compared with 2019.

Conclusion

In this nationwide study, the incidence of hospitalizations for new-onset T1DM and the incidence of diabetic ketoacidosis at diagnosis was not increased during the Covid-19 pandemic in 2020 and 2021. Our results support the fact that infection with SARS-CoV-2 does not promote the development of T1DM.

目的严重急性呼吸系统综合征冠状病毒2型感染与新发1型糖尿病（T1DM）的发展之间的关系尚不清楚。本研究的目的是研究新冠肺炎大流行对法国大都市新发T1DM和糖尿病酮酸中毒诊断住院率的影响。方法这项全国性回顾性队列研究包括2020年和2021年与2019年相比，法国因T1DM发作而住院的所有1至35岁患者的医院数据。结果除了2020年封锁期间的减少外，2020年和2020年因新发T1DM住院的人数与2019年没有显著差异。在受新冠肺炎影响最严重的地区，覆盖7995449名1至35岁的居民，2020年和2021年的标准化住院率与2019年相比没有显著差异。与2019年相比，2020年第14周后和2021年糖尿病酮酸中毒诊断住院人数没有显著差异。结论在这项全国性研究中，2020年和2021年新冠肺炎大流行期间，新发T1DM的住院发病率和糖尿病酮酸血症诊断发病率没有增加。我们的研究结果支持这样一个事实，即感染严重急性呼吸系统综合征冠状病毒2型不会促进T1DM的发展。

{"title":"Incidence of new-onset type 1 diabetes during Covid-19 pandemic: A French nationwide population-based study","authors":"Anne-Sophie Mariet , Jean-Michel Petit , Eric Benzenine , Catherine Quantin , Benjamin Bouillet","doi":"10.1016/j.diabet.2023.101425","DOIUrl":"10.1016/j.diabet.2023.101425","url":null,"abstract":"<div><h3>Aim</h3><p>The association between infection with SARS-CoV-2 and the development of new-onset type 1 diabetes mellitus (T1DM) is unclear. The aim of this study was to examine the impact of the Covid-19 pandemic on the hospitalization rates for new-onset T1DM and diabetic ketoacidosis at diagnosis, in metropolitan France.</p></div><div><h3>Methods</h3><p>This nationwide retrospective cohort study included hospital data on all patients aged 1 to 35 years old, hospitalized in France due to onset of T1DM, in 2020 and 2021 compared to 2019.</p></div><div><h3>Results</h3><p>Apart from a decrease during the lockdown in 2020, the number of hospitalizations due to new-onset T1DM was not significantly different in 2020 and 2021 than it was in 2019. In the regions most affected by Covid-19 and covering 7,995,449 inhabitants aged from 1 to 35 years old, standardized hospitalization rates were not significantly different in 2020 and in 2021 compared with 2019. The number of hospitalizations for diabetic ketoacidosis at diagnosis was not significantly different after week 14 in 2020 and in 2021 compared with 2019.</p></div><div><h3>Conclusion</h3><p>In this nationwide study, the incidence of hospitalizations for new-onset T1DM and the incidence of diabetic ketoacidosis at diagnosis was not increased during the Covid-19 pandemic in 2020 and 2021. Our results support the fact that infection with SARS-CoV-2 does not promote the development of T1DM.</p></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":null,"pages":null},"PeriodicalIF":7.2,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9842656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9840718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Comment on Orsi et al. Retinopathy as an independent predictor of all-cause mortality in individuals with type 2 diabetes [Diabetes Metab, 2023 Mar, 101413] 评论Orsi等人。视网膜病变作为2型糖尿病患者全因死亡率的独立预测因子[j] .中国糖尿病杂志，2013年3月，2013。

IF 7.2 2区医学 Q1 Biochemistry, Genetics and Molecular Biology

Diabetes & metabolism

Pub Date : 2023-05-01 DOI: 10.1016/j.diabet.2023.101430

Tibor V. Varga

引用次数: 1

Low levels of osteocalcin, but not CTX or P1NP, are associated with nonalcoholic hepatic steatosis and steatohepatitis 低水平的骨钙素，而不是CTX或P1NP，与非酒精性肝性脂肪变性和脂肪性肝炎有关

IF 7.2 2区医学 Q1 Biochemistry, Genetics and Molecular Biology

Diabetes & metabolism

Pub Date : 2023-03-01 DOI: 10.1016/j.diabet.2022.101397

Da Fang , Hongli Yin , Xinlu Ji , Haixiang Sun , Xiaoyu Zhao , Yan Bi , Tianwei Gu

Aim

The association of bone turnover with the incidence and progression of nonalcoholic fatty liver disease (NAFLD) is unclear. We aimed to evaluate serum levels of bone turnover markers in relation to NAFLD and nonalcoholic hepatic steatohepatitis (NASH).

Methods

Two cohorts were involved in our study. For the first cohort, 370 participants without NAFLD were retrospectively recruited and followed up for incident NAFLD according to ultrasound. For the second cohort, 562 subjects who underwent liver biopsy were included and grouped into non-NAFLD, non-NASH or NASH according to the NASH Clinical Research Network system. The bone turnover markers osteocalcin, C-terminal telopeptide (CTX) and N-terminal propeptide of type-1 procollagen (P1NP) were measured.

Results

Baseline osteocalcin was significantly lower in subjects who developed NAFLD (13.93 [11.03;16.39] versus 18.24 [15.45;22.47] ng/ml, P < 0.001), with a median of 26.4 months of follow-up. Low levels of osteocalcin, but not CTX or P1NP, was an independent predictor of incident NAFLD (OR 0.755 [95%CI 0.668; 0.855] P < 0.001). Moreover, the osteocalcin level was negatively associated with the degree of liver steatosis. Furthermore, subjects with NASH had significantly lower osteocalcin than non-NASH and non-NAFLD group (13.28 [10.49;16.59] versus 14.91 [12.45;18.09] versus 18.21 [15.04;22.05] ng/ml, all P < 0.001). A low osteocalcin level was an independent risk factor for NASH (OR for highest versus lowest quartile: 0.282 [0.147;0.543] P < 0.001).

Conclusion

Low level of osteocalcin, but not CTX or P1NP, was associated with NAFLD and NASH, indicating its potential role as an important endocrine regulator of hepatic energy metabolism.

目的骨转换与非酒精性脂肪肝（NAFLD）的发病率和进展之间的关系尚不清楚。我们旨在评估血清骨转换标志物水平与NAFLD和非酒精性肝性脂肪性肝炎（NASH）的关系。在第一个队列中，370名无NAFLD的参与者被回顾性招募，并根据超声对发生的NAFLD进行随访。在第二个队列中，根据NASH临床研究网络系统，562名接受肝活检的受试者被纳入并分组为非NAFLD、非NASH或NASH。测定骨转换标志物骨钙素、1型前胶原C末端肽（CTX）和N末端肽（P1NP）。结果NAFLD患者的基线骨钙素显著降低（13.93[11.03；16.39]对18.24[15.45；22.47]ng/ml，P<；0.001），中位随访时间为26.4个月。低水平的骨钙素，而不是CTX或P1NP，是NAFLD事件的独立预测因子（or 0.755[95%CI 0.668；0.855]P<；0.001）。此外，骨钙素水平与肝脂肪变性程度呈负相关。此外，NASH受试者的骨钙素水平显著低于非NASH和非NAFLD组（13.28[10.49；16.59]对14.91[12.45；18.09]对18.21[15.04；22.05]ng/ml，均P<；0.001），而不是CTX或P1NP，与NAFLD和NASH相关，表明其作为肝脏能量代谢的重要内分泌调节因子的潜在作用。

{"title":"Low levels of osteocalcin, but not CTX or P1NP, are associated with nonalcoholic hepatic steatosis and steatohepatitis","authors":"Da Fang , Hongli Yin , Xinlu Ji , Haixiang Sun , Xiaoyu Zhao , Yan Bi , Tianwei Gu","doi":"10.1016/j.diabet.2022.101397","DOIUrl":"10.1016/j.diabet.2022.101397","url":null,"abstract":"<div><h3>Aim</h3><p>The association of bone turnover with the incidence and progression of nonalcoholic fatty liver disease (NAFLD) is unclear. We aimed to evaluate serum levels of bone turnover markers in relation to NAFLD and nonalcoholic hepatic steatohepatitis (NASH).</p></div><div><h3>Methods</h3><p>Two cohorts were involved in our study. For the first cohort, 370 participants without NAFLD were retrospectively recruited and followed up for incident NAFLD according to ultrasound. For the second cohort, 562 subjects who underwent liver biopsy were included and grouped into non-NAFLD, non-NASH or NASH according to the NASH Clinical Research Network system. The bone turnover markers osteocalcin, C-terminal telopeptide (CTX) and N-terminal propeptide of type-1 procollagen (P1NP) were measured.</p></div><div><h3>Results</h3><p>Baseline osteocalcin was significantly lower in subjects who developed NAFLD (13.93 [11.03;16.39] versus 18.24 [15.45;22.47] ng/ml, <em>P</em> < 0.001), with a median of 26.4 months of follow-up. Low levels of osteocalcin, but not CTX or P1NP, was an independent predictor of incident NAFLD (OR 0.755 [95%CI 0.668; 0.855] <em>P</em> < 0.001). Moreover, the osteocalcin level was negatively associated with the degree of liver steatosis. Furthermore, subjects with NASH had significantly lower osteocalcin than non-NASH and non-NAFLD group (13.28 [10.49;16.59] versus 14.91 [12.45;18.09] versus 18.21 [15.04;22.05] ng/ml, all <em>P</em> < 0.001). A low osteocalcin level was an independent risk factor for NASH (OR for highest versus lowest quartile: 0.282 [0.147;0.543] <em>P</em> < 0.001).</p></div><div><h3>Conclusion</h3><p>Low level of osteocalcin, but not CTX or P1NP, was associated with NAFLD and NASH, indicating its potential role as an important endocrine regulator of hepatic energy metabolism.</p></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":null,"pages":null},"PeriodicalIF":7.2,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9151914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Association between metabolic dysfunction-associated fatty liver disease and supraventricular and ventricular tachyarrhythmias in patients with type 2 diabetes 2型糖尿病患者代谢功能障碍相关脂肪性肝病与室上性和室性心动过速之间的关系

IF 7.2 2区医学 Q1 Biochemistry, Genetics and Molecular Biology

Diabetes & metabolism

Pub Date : 2023-03-01 DOI: 10.1016/j.diabet.2022.101416

Alessandro Mantovani , Alessandro Csermely , Antonio Taverna , Davide Cappelli , Giovanni Benfari , Stefano Bonapace , Christopher D. Byrne , Giovanni Targher

Background

Currently, it remains uncertain whether metabolic dysfunction-associated fatty liver disease (MAFLD) is associated with increased risk of supraventricular and ventricular tachyarrhythmias in people with type 2 diabetes mellitus (T2DM).

Methods

We retrospectively examined the data of 367 ambulatory patients with T2DM who underwent 24-hour Holter monitoring between 2015 and 2022 for clinical indications, and who did not have pre-existing permanent atrial fibrillation (AF), kidney failure or known liver diseases. Paroxysmal supraventricular tachycardia (PSVT), paroxysmal AF and episodes of ventricular tachyarrhythmias (i.e., presence of ventricular tachycardia, >30 premature ventricular complexes per hour, or both) were recorded. The presence and severity of MAFLD was diagnosed by ultrasonography and fibrosis-4 (FIB-4) index.

Results

Patients with T2DM who had MAFLD (n = 238) had a significantly greater prevalence of PSVT (51.7% vs. 38.8%), paroxysmal AF (6.3% vs. 1.3%) and combined ventricular tachyarrhythmias (31.9% vs. 20.2%) compared to their counterparts without MAFLD (n = 129). MAFLD was significantly associated with a greater than two-fold risk of having PSVT (adjusted-odds ratio [OR] 2.04, 95% confidence interval 1.04–4.00) or ventricular tachyarrhythmias (adjusted-OR 2.44, 95%CI 1.16–5.11), after adjusting for age, sex, smoking, alcohol intake, diabetes-related factors, comorbidities, medication use and left ventricular ejection fraction on echocardiography. The risk of supraventricular and ventricular tachyarrhythmias was even greater amongst patients with MAFLD and FIB-4 ≥ 1.3.

Conclusions

In ambulatory patients with T2DM, the presence and severity of MAFLD was strongly associated with an increased risk of supraventricular and ventricular arrhythmias on 24-hour Holter monitoring.

背景目前，尚不确定代谢功能障碍相关脂肪肝（MAFLD）是否与2型糖尿病（T2DM）患者室上性和室性快速性心律失常的风险增加有关。方法我们回顾性检查了367名T2DM门诊患者的数据，这些患者在2015年至2022年间接受了24小时动态心电图监测，以了解其临床适应症，并且他们之前没有永久性心房颤动（AF）、肾衰竭或已知肝病。记录阵发性室上性心动过速（PSVT）、阵发性房颤和室性快速性心律失常发作（即存在室性心动过快，＞每小时30个室性早搏复合物，或两者兼有）。MAFLD的存在和严重程度通过超声和纤维蛋白-4（FIB-4）指数进行诊断。结果有MAFLD的T2DM患者（n=238）的PSVT（51.7%对38.8%）、阵发性房颤（6.3%对1.3%）和合并室性快速心律失常（31.9%对20.2%）的发生率明显高于无MAFLD的患者（n=129）。在对年龄、性别、吸烟、饮酒、糖尿病相关因素、合并症、药物使用和超声心动图左心室射血分数进行调整后，MAFLD与PSVT（调整后比值比[OR]2.04，95%置信区间1.04-4.00）或室性快速心律失常（调整后OR 2.44，95%CI 1.16-5.11）的风险增加两倍以上显著相关。MAFLD和FIB-4≥1.3的患者发生室上性和室性快速性心律失常的风险更大。结论在T2DM的门诊患者中，24小时动态心电图监测显示，MAFLD的存在和严重程度与室上性心律失常和室性心律失常风险增加密切相关。

{"title":"Association between metabolic dysfunction-associated fatty liver disease and supraventricular and ventricular tachyarrhythmias in patients with type 2 diabetes","authors":"Alessandro Mantovani , Alessandro Csermely , Antonio Taverna , Davide Cappelli , Giovanni Benfari , Stefano Bonapace , Christopher D. Byrne , Giovanni Targher","doi":"10.1016/j.diabet.2022.101416","DOIUrl":"10.1016/j.diabet.2022.101416","url":null,"abstract":"<div><h3>Background</h3><p>Currently, it remains uncertain whether metabolic dysfunction-associated fatty liver disease (MAFLD) is associated with increased risk of supraventricular and ventricular tachyarrhythmias in people with type 2 diabetes mellitus (T2DM).</p></div><div><h3>Methods</h3><p>We retrospectively examined the data of 367 ambulatory patients with T2DM who underwent 24-hour Holter monitoring between 2015 and 2022 for clinical indications, and who did not have pre-existing permanent atrial fibrillation (AF), kidney failure or known liver diseases. Paroxysmal supraventricular tachycardia (PSVT), paroxysmal AF and episodes of ventricular tachyarrhythmias (i.e., presence of ventricular tachycardia, >30 premature ventricular complexes per hour, or both) were recorded. The presence and severity of MAFLD was diagnosed by ultrasonography and fibrosis-4 (FIB-4) index.</p></div><div><h3>Results</h3><p>Patients with T2DM who had MAFLD (<em>n</em> = 238) had a significantly greater prevalence of PSVT (51.7% vs. 38.8%), paroxysmal AF (6.3% vs. 1.3%) and combined ventricular tachyarrhythmias (31.9% vs. 20.2%) compared to their counterparts without MAFLD (<em>n</em> = 129). MAFLD was significantly associated with a greater than two-fold risk of having PSVT (adjusted-odds ratio [OR] 2.04, 95% confidence interval 1.04–4.00) or ventricular tachyarrhythmias (adjusted-OR 2.44, 95%CI 1.16–5.11), after adjusting for age, sex, smoking, alcohol intake, diabetes-related factors, comorbidities, medication use and left ventricular ejection fraction on echocardiography. The risk of supraventricular and ventricular tachyarrhythmias was even greater amongst patients with MAFLD and FIB-4 ≥ 1.3.</p></div><div><h3>Conclusions</h3><p>In ambulatory patients with T2DM, the presence and severity of MAFLD was strongly associated with an increased risk of supraventricular and ventricular arrhythmias on 24-hour Holter monitoring.</p></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":null,"pages":null},"PeriodicalIF":7.2,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9527497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Lipoatrophic diabetes in familial partial lipodystrophy type 2: From insulin resistance to diabetes 家族性部分脂肪营养不良2型的脂肪萎缩性糖尿病:从胰岛素抵抗到糖尿病

IF 7.2 2区医学 Q1 Biochemistry, Genetics and Molecular Biology

Diabetes & metabolism

Pub Date : 2023-03-01 DOI: 10.1016/j.diabet.2022.101409

Guillaume Treiber , Alice Guilleux , Kevin Huynh , Oriane Bonfanti , Ania Flaus–Furmaniuk , David Couret , Natalie Mellet , Céline Bernard , Nathalie Le-Moullec , Berenice Doray , Isabelle Jéru , Jean-Christophe Maiza , Bhoopendrasing Domun , Muriel Cogne , Olivier Meilhac , Corinne Vigouroux , Peter J Meikle , Estelle Nobécourt

Aim

Subjects with Familial Partial Lipodystrophy type 2 (FPLD2) are at high risk to develop diabetes. To better understand the natural history and variability of this disease, we studied glucose tolerance, insulin response to an oral glucose load, and metabolic markers in the largest cohort to date of subjects with FPLD2 due to the same LMNA variant.

Methods

A total of 102 patients aged > 18 years, with FPLD2 due to the LMNA ‘Reunionese’ variant p.(Thr655Asnfs*49) and 22 unaffected adult relatives with normal glucose tolerance (NGT) were enrolled. Oral Glucose Tolerance Tests (OGTT) with calculation of derived insulin sensitivity and secretion markers, and measurements of HbA1c, C-reactive protein, leptin, adiponectin and lipid profile were performed.

Results

In patients with FPLD2: 65% had either diabetes (41%) or prediabetes (24%) despite their young age (median: 39.5 years IQR 29.0-50.8) and close-to-normal BMI (median: 25.5 kg/m² IQR 23.1-29.4). Post-load OGTT values revealed insulin resistance and increased insulin secretion in patients with FPLD2 and NGT, whereas patients with diabetes were characterized by decreased insulin secretion. Impaired glucose tolerance with normal fasting glucose was present in 86% of patients with prediabetes. Adiponectin levels were decreased in all subjects with FPLD2 and correlated with insulin sensitivity markers.

Conclusions

OGTT reveals early alterations of glucose and insulin metabolism in patients with FPLD2, and should be systematically performed before excluding a diagnosis of prediabetes or diabetes to adapt medical care. Decreased adiponectin is an early marker of the disease. Adiponectin replacement therapy warrants further study in FPLD2.

目的2型家族性部分性脂营养不良（FPLD2）患者发生糖尿病的风险较高。为了更好地了解这种疾病的自然史和变异性，我们在迄今为止因相同LMNA变体而患有FPLD2的最大队列中研究了葡萄糖耐量、胰岛素对口服葡萄糖负荷的反应和代谢标志物。方法对102例年龄>；18岁，由于LMNA“Reunionese”变体p导致FPLD2。（Thr655Asnfs*49）和22名具有正常葡萄糖耐量（NGT）的未受影响的成年亲属被纳入研究。进行口服葡萄糖耐量试验（OGTT），计算衍生的胰岛素敏感性和分泌标志物，并测量HbA1c、C反应蛋白、瘦素、脂联素和脂质状况。结果在FPLD2患者中：65%的患者尽管年龄较小（中位数：39.5岁，IQR 29.0-50.8）且接近正常BMI（中位数：25.5kg/m2，IQR 23.1-29.4），但仍患有糖尿病（41%）或糖尿病前期（24%）。负荷后OGTT值显示FPLD2和NGT患者存在胰岛素抵抗和胰岛素分泌增加，而糖尿病患者的特征是胰岛素分泌减少。86%的糖尿病前期患者存在空腹血糖正常的糖耐量受损。所有FPLD2受试者的脂联素水平均降低，并与胰岛素敏感性标志物相关。结论sOGTT揭示了FPLD2患者葡萄糖和胰岛素代谢的早期变化，在排除糖尿病前期或糖尿病的诊断之前，应进行系统的检查，以适应医疗护理。脂联素降低是该疾病的早期标志。脂联素替代疗法值得进一步研究FPLD2。

{"title":"Lipoatrophic diabetes in familial partial lipodystrophy type 2: From insulin resistance to diabetes","authors":"Guillaume Treiber , Alice Guilleux , Kevin Huynh , Oriane Bonfanti , Ania Flaus–Furmaniuk , David Couret , Natalie Mellet , Céline Bernard , Nathalie Le-Moullec , Berenice Doray , Isabelle Jéru , Jean-Christophe Maiza , Bhoopendrasing Domun , Muriel Cogne , Olivier Meilhac , Corinne Vigouroux , Peter J Meikle , Estelle Nobécourt","doi":"10.1016/j.diabet.2022.101409","DOIUrl":"10.1016/j.diabet.2022.101409","url":null,"abstract":"<div><h3>Aim</h3><p>Subjects with Familial Partial Lipodystrophy type 2 (FPLD2) are at high risk to develop diabetes. To better understand the natural history and variability of this disease, we studied glucose tolerance, insulin response to an oral glucose load, and metabolic markers in the largest cohort to date of subjects with FPLD2 due to the same LMNA variant.</p></div><div><h3>Methods</h3><p>A total of 102 patients aged > 18 years, with FPLD2 due to the LMNA ‘Reunionese’ variant p.(Thr655Asnfs*49) and 22 unaffected adult relatives with normal glucose tolerance (NGT) were enrolled. Oral Glucose Tolerance Tests (OGTT) with calculation of derived insulin sensitivity and secretion markers, and measurements of HbA1c, C-reactive protein, leptin, adiponectin and lipid profile were performed.</p></div><div><h3>Results</h3><p>In patients with FPLD2: 65% had either diabetes (41%) or prediabetes (24%) despite their young age (median: 39.5 years IQR 29.0-50.8) and close-to-normal BMI (median: 25.5 kg/m<sup>2</sup> IQR 23.1-29.4). Post-load OGTT values revealed insulin resistance and increased insulin secretion in patients with FPLD2 and NGT, whereas patients with diabetes were characterized by decreased insulin secretion. Impaired glucose tolerance with normal fasting glucose was present in 86% of patients with prediabetes. Adiponectin levels were decreased in all subjects with FPLD2 and correlated with insulin sensitivity markers.</p></div><div><h3>Conclusions</h3><p>OGTT reveals early alterations of glucose and insulin metabolism in patients with FPLD2, and should be systematically performed before excluding a diagnosis of prediabetes or diabetes to adapt medical care. Decreased adiponectin is an early marker of the disease. Adiponectin replacement therapy warrants further study in FPLD2.</p></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":null,"pages":null},"PeriodicalIF":7.2,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9206803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Dulaglutide and insulin microsecretion in people with type 1 diabetes (DIAMOND-GLP-1): A randomized double-blind placebo-controlled trial 杜拉鲁肽和1型糖尿病患者胰岛素微分泌(DIAMOND-GLP-1):一项随机双盲安慰剂对照试验

IF 7.2 2区医学 Q1 Biochemistry, Genetics and Molecular Biology

Diabetes & metabolism

Pub Date : 2023-03-01 DOI: 10.1016/j.diabet.2023.101433

Charles Thivolet , Etienne Larger , Bertrand Cariou , Eric Renard , Hélène Hanaire , Pierre-Yves Benhamou , Bruno Guerci , Émilie Mathiotte , Karim Chikh

引用次数: 0

首页上一页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Diabetes & metabolism

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀